Research analysts who have asked questions during Inventiva earnings calls.
Delphine Le Louet
Societe Generale
1 question for IVA
Evan Wang
Guggenheim Securities
1 question for IVA
Also covers: ARCT, BOLD, IVVD +1 more
Jean-Jacques Le Fur
Bryan, Garnier & Co
1 question for IVA
Jeroen Van den Bossche
KBC Securities
1 question for IVA
Lucy-Emma Codrington-Bartlett
Jefferies Financial Group Inc.
1 question for IVA
Also covers: NBTX, ZLDPF
Recent press releases and 8-K filings for IVA.
Inventiva Updates on Lanifibranor Phase 3 and Commercial Strategy
IVA
New Projects/Investments
Product Launch
Guidance Update
- Inventiva recently completed a successful fundraising to strengthen its balance sheet.
- The Phase 3 NATIVE 3 study for lanifibranor in MASH F2 and F3 patients was fully enrolled in April 2025 and is expected to have a data readout in the second half of 2026.
- The company is preparing for the market entry of lanifibranor, positioning it as an oral therapy for MASH F2 and F3 patients, highlighting its antifibrotic and antidiabetic effects.
- Inventiva plans to file the NDA for the U.S. first, followed by the MAA for the EMA, expeditiously after 2027, and is building its commercial and regulatory teams in 2026.
4 days ago
Inventiva Announces Full Exercise of Underwriters' Option, Bringing Offering Proceeds to $172.5M
IVA
- On November 17, 2025, Inventiva announced the full exercise of the underwriters' option to purchase 5,844,155 additional American Depositary Shares (ADSs).
- This exercise increased the total number of ADSs issued in the offering to 44,805,193.
- The full exercise of the option resulted in approximately $172.5 million in gross proceeds and an estimated $161.2 million in net proceeds for the company.
- The offering price for each ADS was $3.85.
- The additional ADSs are expected to be delivered on November 18, 2025.
Nov 17, 2025, 11:05 AM
Inventiva S.A. Reports Increased Net Loss in H1 2025 Amid Strategic Restructuring and Financing Activities
IVA
Earnings
Layoffs
New Projects/Investments
- Inventiva S.A. reported a net loss of €175.9 million for the first half of 2025, a significant increase from the €49.0 million net loss in the first half of 2024, primarily due to a €113.2 million net financial loss.
- The company completed patient enrollment in its NATiV3 Phase 3 clinical trial for lanifibranor on April 1, 2025, with topline results for Part 1 targeted for the second half of 2026.
- In February 2025, Inventiva S.A. implemented a Strategic Pipeline Prioritization Plan to focus exclusively on lanifibranor development, which included a workforce reduction of approximately 50%.
- Inventiva S.A. secured the €116 million second tranche of its structured financing on May 5, 2025, and received a $10 million milestone payment from CTTQ on July 7, 2025, contributing to €4.5 million in revenues for the first half of 2025.
- As of June 30, 2025, the company held €122.1 million in cash and cash equivalents.
Oct 14, 2025, 8:39 PM
Inventiva Provides Update on Lanifibranor Phase 3 Trial and Management Changes
IVA
CEO Change
Management Change
New Projects/Investments
- Inventiva (IVA) recently appointed Andrew Ovenshain as CEO and strengthened its management team, following a $400+ million PIPE raise approximately a year ago.
- The global Phase 3 NATIVE 3 trial for its MASH therapy, lanifibranor, was fully enrolled in April 2025, with top-line results anticipated in the second half of 2026 and a commercial launch targeted for 2028.
- Lanifibranor, a pan-PPAR agonist, showed an 18% improvement in fibrosis in six months in Phase 2b data and is positioned to address the significant unmet need in the MASH market, which is currently 10% diagnosed out of 18 million US patients.
Oct 8, 2025, 4:00 PM
Inventiva Appoints Andrew Obenshain as CEO
IVA
CEO Change
Management Change
Board Change
- Inventiva announced the appointment of Andrew Obenshain as its new Chief Executive Officer (CEO), effective October 1, 2025.
- Mr. Obenshain will also join the Company’s Board of Directors.
- He succeeds co-founder Frédéric Cren, who served as CEO for 13 years and is also stepping down from the Board of Directors.
- This leadership transition is a strategic decision to support Inventiva's next stage of growth, with a focus on preparing for potential commercialization in the United States for MASH and building a global footprint.
- Mr. Obenshain brings over 20 years of global leadership experience in drug development, regulatory strategy, and commercialization, including his previous role as CEO of bluebird bio.
Oct 1, 2025, 10:05 AM
Inventiva Appoints New Chief Executive Officer
IVA
CEO Change
Management Change
Hiring
- Inventiva announced the appointment of Andrew Obenshain as its new Chief Executive Officer, effective October 1, 2025.
- Mr. Obenshain succeeds co-founder Frédéric Cren, who served as CEO since the company's inception in 2012.
- This leadership transition is a strategic decision to support Inventiva's next stage of growth, with a particular focus on preparing for potential commercialization in the United States and expanding its global footprint.
- Andrew Obenshain brings over 20 years of global leadership experience in drug development, regulatory strategy, and commercialization, having previously been the CEO of bluebird bio.
Oct 1, 2025, 6:32 AM
Inventiva Reports H1 2025 Financial Results and Corporate Update
IVA
Earnings
Guidance Update
Layoffs
- Inventiva reported €4.5 million in revenues for the first half of 2025, a significant increase from the same period in 2024, and a net loss of €(175.9) million for the period ended June 30, 2025.
- As of June 30, 2025, the company held €122.1 million in cash and cash equivalents and €24.6 million in short-term deposits, with a cash runway currently planned until the end of the third quarter of 2026.
- The company completed enrollment for its pivotal Phase 3 NATiV3 clinical trial in April 2025, with topline results anticipated in the second half of 2026.
- Inventiva reinforced its financial position by receiving €115.6 million in gross proceeds from the second tranche of its structured financing in May 2025 and implemented a pipeline prioritization plan in February 2025, including a 50% workforce reduction, to focus exclusively on lanifibranor development.
Sep 29, 2025, 11:23 AM
Inventiva Reports H1 2025 Financial Results and Corporate Update
IVA
Earnings
Guidance Update
Layoffs
- Inventiva reported revenues of €4.5 million and a net loss of (€175.9) million for the first half of 2025.
- As of June 30, 2025, cash and cash equivalents, including short-term deposits, amounted to €146.7 million, with a cash runway planned until the end of the third quarter of 2026.
- The company received €115.6 million from the second tranche of its structured financing in May 2025, following the completion of enrollment for the Phase 3 NATiV3 clinical trial in April 2025.
- Topline results for the NATiV3 trial are expected in the second half of 2026.
- Inventiva is implementing a pipeline prioritization plan, which includes a workforce reduction of approximately 50%.
Sep 29, 2025, 6:32 AM
Quarterly earnings call transcripts for Inventiva.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more